baseline, with a minimum six point increase in PASI score compared to
week 33) compared to patients on placebo (28 percent).
-- In CHAMPION, a pivotal 16-week study evaluating 271 psoriasis patients
from eight European countries and Canada, HUMIRA-treated patients
experienced a significant reduction in the signs and symptoms of their
disease compared with methotrexate or placebo-treated patients, with
more than twice the percentage (80 percent) of patients treated with
HUMIRA achieving a PASI 75 response compared to patients treated with
methotrexate (36 percent), a standard systemic treatment for
psoriasis, and more than four times the percentage of patients treated
with placebo (19 percent).
Nearly 17 percent of patients treated with HUMIRA achieved a PASI 100
response at week 16, compared to 7 percent of patients receiving
methotrexate and 2 percent of patients receiving placebo. In
addition, a mean percentage PASI improvement of 57 percent was
achieved at week four in patients receiving HUMIRA, compared to
The most commonly reported adverse events in HUMIRA psoriasis trials were nasopharyngitis (inflammation of the nose and pharynx), upper respiratory tract infection and headache.
More Information About Psoriasis
Psoriasis is a chronic autoimmune disease that speeds the growth cycle of skin cells and results in thick scaly areas of skin. The most common form of psoriasis appears as red, raised areas of skin covered with flaky white scales, which may itch or burn. Psoriasis most commonly appears on the scalp, knees, elbows, lower back, hands and feet, though it can develop anywhere on the skin. It may even occur in the fingernails and toenails.
While psoriasis can occur in people of all ages, it typic
Copyright©2007 PR Newswire.
All rights reserved